Semola

Semola is a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company leverages a proprietary drug discovery platform that integrates structural biology, computational chemistry, and advanced screening techniques to identify highly selective modulators for historically challenging GPCR targets. Semola's current pipeline is primarily directed toward addressing unmet needs in metabolic disorders, chronic inflammation, and neurodegenerative diseases. By focusing on precision pharmacology, the company aims to develop next-generation treatments with improved efficacy and safety profiles compared to existing therapies.